The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase 2 study SAKK 33/14 (Q58580502)
Jump to navigation
Jump to search
scientific article published on 08 November 2018
- The sympathomimetic agonist mirabegron did not lower -V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase 2 study SAKK 33/14 |
scientific article published on 08 November 2018 |
|
Statements
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14 (English)
Swiss Group for Clinical Cancer Research (SAKK)
Beatrice Drexler
Martin Bigler
Nathan Cantoni
Peter Keller
Georg Stussi
Axel Ruefer
Rudolf Benz
Geneviève Favre
Pontus Lundberg
Ronny Nienhold
Andrea Fuhrer
Christine Biaggi
Markus G Manz
Mario Bargetzi
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference